持续葡萄糖监测改善血液透析合并2型糖尿病患者的血糖波动检出
这项前瞻性观察研究纳入59例接受血液透析至少90天的胰岛素治疗2型糖尿病成人患者,比较持续葡萄糖监测(CGM)与毛细血管血糖检测(CBG)对血糖波动的检出。CGM测得的平均葡萄糖更高、目标范围内时间更低,并检出更多低血糖事件,尤其是夜间和持续性低血糖,还揭示了与透析相关的血糖模式。
要点
- CGM测得的平均葡萄糖为188.9±45.0,CBG为165.7±41.8,CGM目标范围内时间为51%±26,CBG为68%±23(P<.001)。
- CGM检出47%患者有低于70 mg/dL的低血糖,CBG检出25%(P=.005);低于54 mg/dL的低血糖分别为25%和12%(P=.08)。
- 夜间和持续性低于70 mg/dL的低血糖仅由CGM检出,分别为29%和12%。
核心结论
- 在血液透析合并2型糖尿病和终末期肾病患者中,CGM改善了高血糖和低血糖事件的检出,尤其是夜间和持续性低血糖。
- CGM揭示了与透析 session 相关的独特血糖模式,可能有助于更个性化的管理。
研究设计与样本
- 前瞻性观察性研究,纳入59例接受血液透析90天或以上的胰岛素治疗2型糖尿病成人患者,佩戴Dexcom G6-Pro CGM,并指导每日最多进行4次毛细血管血糖检测。
主要发现
- CBG和CGM测得的平均葡萄糖分别为165.7±41.8和188.9±45.0,目标范围内时间分别为68%±23和51%±26(P<.001)。
- CGM检出所有参与者均有180 mg/dL的高血糖事件,高于180 mg/dL的时间为47.8%±27;90%的参与者有大于250 mg/dL的事件,高于250 mg/dL的时间为20.9%±21.7。
- CGM检出低于70 mg/dL的低血糖比例为47%,CBG为25%(P=.005);低于54 mg/dL的低血糖比例CGM为25%,CBG为12%(P=.08)。
- 夜间和持续性低于70 mg/dL的低血糖仅由CGM检出,分别为29%和12%。
- CGM显示透析前日血糖水平改善、透析期间血糖较低、透析后期间血糖快速升高的模式。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Optimal glucose management in individuals with type 2 diabetes (T2D) and end-stage kidney disease (ESKD) on hemodialysis is challenging. OBJECTIVE: We compared the detection of glycemic excursions with continuous glucose monitoring (CGM) and capillary blood glucose testing (CBG) in this population. METHODS: In this prospective observational study, insulin-treated adults with T2D on hemodialysis for 90 or more days wore a Dexcom G6-Pro CGM. Participants were instructed to perform CBG testing up to 4 times daily. We compared differences in glucose metrics and described CGM patterns in relation to dialysis sessions. RESULTS: Among 59 participants (age 57.7 ± 9 years, glycated hemoglobin A1c 7.09%), mean glucose measured by CBG and CGM was 165.7 ± 41.8 and 188.9 ± 45.0, with a time-in-range (TIR) of 68% ± 23 and 51% ± 26, respectively (P < .001). CGM detected that all participants had hyperglycemic episodes of 180 mg/dL, with time above range (TAR) of 180 mg/dL of 47.8% ± 27, and 90% had episodes greater than 250 mg/dL, with TAR greater than 250 mg/dL of 20.9% ± 21.7. CGM detected higher rates of hypoglycemia of less than 70 mg/dL, (47% vs 25%; P = .005) and less than 54 mg/dL, (25% vs 12%; P = .08) compared with CBG testing. Nocturnal and prolonged hypoglycemia less than 70 mg/dL were detected only by CGM (29% and 12%, respectively). CGM showed a pattern of improved glucose levels on predialysis days, lower glucose levels during hemodialysis, and a rapid rise during the postdialysis period. CONCLUSION: In participants with T2D and ESKD on hemodialysis, CGM improved the detection of hyperglycemic and hypoglycemic events, particularly nocturnal and prolonged episodes. CGM revealed distinct glycemic patterns related to dialysis sessions, potentially enabling more personalized management.
引用
- Galindo RJ, Moazzami B, Gerges A, et al. Continuous Glucose Monitoring Improves Detection of Glycemic Excursions in Hemodialysis Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 40119833. doi:10.1210/clinem/dgaf187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。